Ajuts a la recerca

Therapeutic Pipeline Program - Fall 2013- Michael J. Fox Foundation

Organisme

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) seeks to fund both preclinical and clinical development of therapeutics that may alter the course of PD progression

Objecte

The goal of the Therapeutic Pipeline Program is to support therapeutic development around targets within pathways that have been implicated in altering the course of Parkinson’s disease (disease modifying strategies). The pathways selected are of interest to PD given their presumed role in the pathophysiology of disease progression involving environmental toxins, protein handling, inflammatory mediators and genes associated with select populations of carriers.

Although most traditional therapies involve pharmacological approaches, MJFF is also open to alternative strategies, including gene therapy, biological, surgical and non-invasive/non-pharmaceutical approaches that can have significant impact for patients. Moreover, as drug targets may be shared among multiple diseases and/or drugs may hit multiple disease targets, MJFF is also interested in drug repositioning of molecules for PD that have been approved or shown to be clinically safe for other indications.

Descripció

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) seeks to fund both preclinical and clinical development of therapeutics that may alter the course of PD progression and that focus on targets within the following specific pathways:

• Mitochondrial Function
• Inflammation
• Unfolded Protein Response/Autophagy
• Targets involved in genetic forms of PD

PLEASE NOTE: Proposals focused on alpha-synuclein and LRRK2 will not be considered as a part of this request for applications

Applicant will be asked to justify the therapeutic targets relevant for PD and provide details of the therapeutic strategy. Considerations include:

The target and pathway proposed:
What is the relevance of the proposed target for PD?
What is the relationship of the proposed target within the pathway in which it is implicated to other potential targets?
Why is the proposed target the most relevant in that pathway – in comparison to other targets in the same pathway?
Is the target a master regulator of the pathway, or is it more downstream?

The therapeutic strategy:
What is your research operation plan, including feasibility and timelines?
What is your experimental design?
Which assays and model systems are you planning to use?
If you are utilizing a small-molecule approach, what are the properties of your compound that suggest it is an ideal tool compound or therapeutic?

There is no set budget limit for proposals and applicants may request up to two years of funding for preclinical development or up to three years of funding for clinical development.
 

Termini oficial

Informational Conference Call*: March 7, 2013, 12:00 p.m. EST
Pre-proposals Due: April 3, 2013, 6:00 p.m. EST
Full Application Invites Sent to Applicants: April 24, 2013
Full Applications Due: June 12, 2013
Anticipated Award Announcement: September 2013
Anticipated Funding: October 2013

Termini IISPV

Cal comunicar abans del 5 de març de 2013 que es vol participar a la convocatòria, enviant un e-mail a convocatories@iispv.cat . Termini: 21 de març de 2013

Pujar